Dear SAPA-GP members and friends,
Here is a friendly reminder regarding SAPA-GP partners' events: Precision Medicine and Immuno-oncology China Summit 2017. It's going to take place on April 25-26, 2017 in Shanghai, China.
The Precision Medicine and Immuno-oncology China Summit 2017 is the leading industry platform in China for precision medicine and immunotherapy industry leaders to meet, network and discuss current technology trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia.
Featuring Keynote Presentations:
Opening Address and Introduction
Bin SHI, President, SAPA-GP
Precision Medicine in CRC Treatment
Jin LI, Director, Department of Medical Oncology, Shanghai East Hospital affiliated to Tongji University, Shanghai China
Bispecific Antibody T-Cell Engager for Cancer Immunotherapy
Mingqiang ZHANG, Vice President, Amgen Biopharmaceutical
PARP Inhibitors: BRCA and Beyond
Min HU, Principal Scientist, Genetics Team Leader Biomarker, Asia & Emerging Markets iMed, AstraZeneca China
The Clinical Role of Liquid Biopsy in Cancer Metastasis, Prevention and Treatment
Lunxiu QIN, Associate Dean & Head of Surgery, Huanshan Hospital
Application of mRNA as a Monitoring Tool to Diagnose and Prognose Cancers at Early Phase
Jiaxin PAN, R&D Director, PATH Labs
And 40+ Eminent Speakers with 4 Breakout Sessions
Special Thanks to Sino Biological Inc.
Founded by MIT professor, Dr. Daniel I.C. Wang and his former student, Dr. Liangzhi Xie in 2007, Sino Biological Inc. is a world leading biological manufacturer located in BDA, Beijing , offering a comprehensive set of premium quality reagents, all of which are produced in-house. It also provides one-stop services for protein and antibody discovery, research, development, production and commercialization. The product application covers a broad range of life science research and drug development such as immunology, cell biology, oncology, neuroscience, stem cell, virus, etc. Sino Biological is also dedicated to research and development of biological pharmaceuticals such as monoclonal antibodies, recombinant protein drugs, virus vaccines and rapid diagnosis.